Kowa Company, Ltd.
Since its foundation as a cotton fabric wholesaler in Japan in 1894, Kowa has grown into a multinational Japanese company actively engaged in a broad variety of manufacturing and trading activities which include the fields of pharmaceutical, life science and information technology, textiles, machinery and consumer products. Kowa’s activities continue to develop globally with a focus on health and the environment.
Kowa Pharmaceutical Europe Co. Ltd.
In 1947, the privately-held multinational company Kowa Company, Ltd. of Nagoya, Japan, established its pharmaceutical division in order to research, develop, manufacture and market over-the-counter (OTC) drugs, healthcare products, prescription medicines and medical devices.
In 2000, Kowa Company, Ltd. expanded its global presence by establishing Kowa Pharmaceutical Europe Co. Ltd. This represented a significant step forward in the company’s vision of creating a global pharmaceutical organisation.
The first pharmaceutical product launched by Kowa Pharmaceutical Europe Co. Ltd. was Livazo® (pitavastatin), a potent HMG-CoA reductase inhibitor (statin) for the treatment of primary hyperlipidemia and combined (mixed) dyslipidemia.
Adverse Event Reporting
Kowa routinely monitors the safety of all its pharmaceutical products and devices. This includes review of safety data from clinical studies, and collection of reports and cases of adverse events for marketed products.
Patients and Volunteers in clinical trials reporting an adverse event must contact the investigator.
For specific medical information requests please contact the partner responsible for distribution in your country.
For reporting adverse events within Europe Union please contact local distributor or Recordati
For reporting adverse events within Middle East and North Africa (MENA) please contact...
If you cannot find the information you require please get in touch.